FDA places partial clinical hold on David Hung biotech after certain cancer patients experience eye inflammation - Endpoints News

6/27/2022 12:00:00 AM2 years 10 months ago
by Paul Schloesser

Two and a half years after setting out on another foray into oncology R&D, a biotech headed by David Hung — of Medivation fame — has run into its first setback. San Francisco-based Nuvation Bio announced early Monday the FDA placed a partial clinical hold on …

Two and a half years af­ter set­ting out on an­oth­er for­ay in­to on­col­o­gy R&D, a biotech head­ed by David Hung — of Medi­va­tion fame — has run in­to its first set­back. San Fran­cis­co-bas… [+2878 chars]

full article...